Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Ioannis Vamvakaris, MD, PhD, MSc
Advertisement
Articles by Ioannis Vamvakaris, MD, PhD, MSc
Advertisement
Latest Updated Articles
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETsPublished: July 10th 2024 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
2
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
5
